MAPT and supranuclear palsy, progressive, 1: Although there is still a need to determine the clinical utility of biomarkers for PSP, future studies would also benefit from incorporating neuroimaging, biofluid and electrophysiological biomarkers [e.g., PET with tau-specific ligands, cerebrospinal fluid tau RT-QuIC (30, 31)] to provide more insight to gene-environment interactions and to strengthen the findings in clinically-diagnosed patients.